HIV Flashcards
cells infected by HIV
CD4 T cells
macrophages
dendritic cells
HIV important glycoproteins and their function
gp120 - binds CD4 receptor and co-receptor (CXCR4 or CCR5)
gp41 - promotes fusion of viral and cellular membranes
Risk of MTCT - without intervention
- with BF
- with HAART
15-40% without intervention
15-29% from BF
<2% with HAART
Acute HIV infection - time after
3-10 weeks
AIDS definition
CD4<14%
AIDs defining illnesses (opportunistic infections)
Clinical manifestiations of CD4 >200
usually asympt Skin candida vaginitis / oral Oral hairy leukoplakia Seb derm Shingles KS Ca CIN/Cx Ca B cell lymphoma Haem ITP anaemia Resp Bact pneumonia Recurrent URTIs Pulm TB Other Neuropathy
Clinical manifestations of CD4 100-200
can be asympt Resp PCP Histoplasmosis / coccidiomycosis Military/extrapulm TB Cardiomyopathy Neuro neuropathies / myelopathy Dementia PML Other wasting NHL
Clinical manifestations of CD4 <100
can be asympt Fungal candida oesophagitis Cryptococcus Viral disseminated CMV Bact disseminated MAC Parasite toxo Microsporidiosis Chronic cryptosporidiosis Ca CNS lymphoma
Benefits of ART
prevent OI, Ca Alter/reverse course of existing OIs Improve/preserve immune ftn ↓ Sx ↑ QOL Restore hope ↓ transmission
NRTI - least to most toxic (roughly)
Lamivudine 3TC Emtricitabine FTC Tenofovir TDF Abacavir ABC Zidovudine AZT Didanosine ddI Stavudine d4T
NRTIs active against hep B
lamivudine 3TC
tenofovir TDF
problem with abacavir (ABC) and how to prevent
hypersensitivity rxn 3-7% - mortality
predict with HLA-B5701 test
NRTI class toxicities
mitochondrial toxicity - neuropathy, LA lipodystrophy myopathy hepatitis pancreatitis hyperlipidaemia
Lactic acidosis RFs
female older age high BMI - esp d4T, ddI, combination + - esp 1st 3/12 Rx
Lactic acidosis Sx
A, N, V, AP pancreatitis, hepatitis SOB, arrhyth multi-organ failure, death = increased anion gap + lactate
Lactic acidosis management
- obtain venous sample w/o tourniquet
- stop ARV if symptomatic + high lactate
- supportive Rx
- no d4T, ddI or AZT in next regimen
- routine monitoring not required
NNRTI class toxicities
rash
hepatotoxicity
NNRTI features
long half-life 2-3 wks
lots of drug interxns
not active vs HIV-2 or group O
risk resistance
preferred TB PI
efavirenz
Nevirapine risk and RFs for it
hypersensitivity rxn (rash, hepatotoxicity) - esp men with CD4>400, women CD4>250
benefits of boosting PIs with ritonavir
increased PI level b/c of less metabolism from cyt p450 inhibition fewer pills more predictable efficacy and activity lower toxicity less resistance
preferred PI in pregnancy
lopinavir/ritonavir
IRIS DDx
relapse resistance drug toxicity new disease process - Rx dilemma: stop/continue ART, stop/change OI Rx, anti-infly agent, immunosuppressives
risks of starting ARV at low CD4
higher risk OI
higher risk toxicity
non-AIDS related complications more common (CVD, Ca, liver, renal disease)
ARVs to avoid in TB
PIs - interxn with rifampicin
NVP - use EFV instead (can use if needed)
Treatment failure WHO definition
Clinical - new/recurrent stage 4 condition (IRIS excluded)
Immunological - fall of CD4 to baseline / 50% from peak
Virological - VL >5000
Indications for TMP/SMX prophylaxis of toxo/PCP
CD4 not available - WHO stages 2,3,4 CD4 available - CD4<350 (LMIC) - WHO stages 3,4 Alt - all PLHIV
3 I’s for HIV/TB
Intensified case finding for active TB
Infection control for TB at all clinical encounters
INH preventive treatment - latent TB prevalence >30%
- all with documented latent TB
Meningitis in HIV pts - causes
cryptococcus TB syphilis bacterial - strep, listeria viral fungal lymphoma
CNS mass lesion in HIV pts - causes
Common - toxo * - tuberculoma - lymphoma Less common - cryptococcoma - PML - bacterial abscess - other (syphilis, tumor, Chagas, Nocardia, Aspergillus)